Aurobindo Pharma Q1 Profit Rises 25%; Board Approves Merger of Three Subsidiaries

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628

reported a strong performance for the first quarter of FY27, with consolidated net profit rising 25.2% year-on-year to ₹1,032 crore. Revenue from operations increased 16.3% to ₹9,150 crore, driven by robust growth in its Europe and U.S. formulations businesses, growth markets, and active pharmaceutical ingredients (API) segment. The company's operating EBITDA grew 20% year-on-year to ₹1,924 crore, while the operating EBITDA margin expanded to 21%, reflecting improved operational efficiency and a favourable product mix. Revenue growth was broad-based, with the Europe business growing 25.6%, growth markets rising 37.7%, and the API business increasing 14.6%. During the quarter, the board also approved the merger of Auro Vaccines Pvt. Ltd., GLS Pharma Ltd., and Apitoria Pharma Pvt. Ltd. with Aurobindo Pharma, subject to regulatory and shareholder approvals, as part of its strategy to simplify the corporate structure and improve operational efficiency. Industry & Economic Impact: The results reflect continued strength in India's pharmaceutical sector, supported by healthy global demand for generic medicines, specialty products, and APIs. Growth across key international markets and improving operating margins demonstrate the sector's resilience and focus on value-added manufacturing. From an economic perspective, sustained growth in pharmaceutical manufacturing supports exports, research and development, skilled employment, and healthcare innovation. Corporate restructuring initiatives that streamline operations can also improve efficiency, strengthen competitiveness, and support long-term industrial growth. Source: The Hindu No Recommendations